THE EFFECTS OF ETANERCEPT AND CABERGOLINE ON ENDOMETRIOTIC IMPLANTS, UTERUS AND OVARIES IN RAT ENDOMETRIOSIS MODEL.
Animals
Cabergoline
/ administration & dosage
Disease Models, Animal
Drug Evaluation, Preclinical
Drug Therapy, Combination
Endometriosis
/ drug therapy
Endometrium
/ drug effects
Etanercept
/ administration & dosage
Female
Humans
Ovary
/ drug effects
Rats
Tumor Necrosis Factor-alpha
/ metabolism
Vascular Endothelial Growth Factor A
/ analysis
Autoimmunity
Cabergoline
Endometriosis
Etanercept
Inflammation
Stem cell
Journal
Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
07
03
2021
revised:
10
05
2021
accepted:
25
05
2021
pubmed:
18
6
2021
medline:
27
1
2022
entrez:
17
6
2021
Statut:
ppublish
Résumé
The pathophysiology of endometriosis is still unknown and treatment options remain controversial. Searches focus on angiogenesis, stem cells, immunologic and inflammatory factors. This study investigated the effects of etanercept and cabergoline on ovaries, ectopic, and eutopic endometrium in an endometriosis rat model. This randomized, placebo-controlled, blinded study included 50 rats, Co(control), Sh(Sham), Cb(cabergoline), E(etanercept), and E + Cb(etanercept + cabergoline) groups. After surgical induction of endometriosis, 2
Identifiants
pubmed: 34139652
pii: S0165-0378(21)00070-X
doi: 10.1016/j.jri.2021.103340
pii:
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Vascular Endothelial Growth Factor A
0
vascular endothelial growth factor A, rat
0
Cabergoline
LL60K9J05T
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103340Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.